Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 113.4% YoY to 36.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 8.60 | — | 2.42 | — | 1.02 | — | 1.01 | — | 3.72 | — | — | — | — |
| — | — | +139.1% | — | -72.6% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.56 | 1.09 | 0.54 | 0.61 | 0.31 | 0.67 | 0.40 | 0.35 | 0.11 | 0.11 | 0.16 | 0.28 | 0.79 |
| — | +63.7% | +36.5% | +74.2% | +185.1% | +491.0% | +142.7% | +27.7% | -86.1% | -74.8% | -85.1% | -83.0% | -53.2% | |
| P/B Ratio | 0.87 | 1.24 | 0.86 | 0.64 | 0.50 | 1.07 | 0.91 | 0.93 | 0.20 | 0.19 | 0.25 | 0.39 | 0.43 |
| — | +15.5% | -6.3% | -30.6% | +153.3% | +459.4% | +261.5% | +138.3% | -54.0% | -54.8% | -65.0% | -62.0% | -67.3% | |
| P/FCF | 2.63 | 2.19 | — | 0.84 | — | — | 0.78 | 2.09 | — | 1.50 | 0.93 | — | — |
| — | — | — | -60.0% | — | — | -15.5% | — | — | -51.6% | — | — | — | |
| EV / EBITDA | 3.74 | 36.75 | 2.28 | 7.66 | 2.66 | 17.23 | 2.74 | — | 3.65 | — | — | — | — |
| — | +113.4% | -17.1% | — | -27.0% | — | — | — | — | — | — | — | — | |
| EV / EBIT | 7.08 | — | 2.98 | 375.45 | 4.09 | — | 3.44 | — | 6.13 | — | — | 18.81 | — |
| — | — | -13.3% | — | -33.2% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Emergent BioSolutions Inc.'s operating margin was -11.2% in Q4 2025, down 44.4 pp QoQ and down 6.3 pp YoY. The trailing four-quarter average of 11.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 55.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.2% | 31.3% | 55.9% | 40.8% | 52.4% | 70.1% | 55.9% | -25.7% | 46.9% | 61.2% | 34.2% | 36.5% | -14.8% |
| — | -55.3% | -0.0% | +258.7% | +11.9% | +14.6% | +63.6% | -170.4% | +416.9% | +76.7% | +60.4% | +361.1% | -143.0% | |
| Operating Margin | 14.8% | -11.2% | 33.2% | 0.4% | 21.9% | -4.9% | 22.0% | -79.9% | 13.2% | -15.8% | -89.5% | -86.7% | -89.8% |
| — | -128.8% | +51.4% | +100.4% | +65.1% | +69.2% | +124.5% | +7.8% | +114.7% | +5.4% | -374.0% | -174.3% | -4416.3% | |
| Net Margin | 7.1% | -36.7% | 22.2% | -8.5% | 30.6% | -16.1% | 39.1% | -111.2% | 3.0% | -17.9% | -97.4% | -77.4% | -113.3% |
| — | -128.4% | -43.3% | +92.3% | +921.5% | +10.2% | +140.1% | -43.7% | +102.6% | +11.8% | -168.2% | -245.0% | -9318.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.5% | -9.9% | 9.2% | -2.2% | 13.1% | -6.3% | 25.7% | -53.9% | 1.4% | -7.4% | -31.9% | -24.2% | -14.4% |
| — | -56.5% | -64.3% | +95.9% | +858.2% | +14.1% | +180.5% | -122.6% | +109.5% | -55.7% | -441.8% | -595.1% | -6091.5% | |
| ROA | 3.9% | -3.9% | 3.6% | -0.8% | 4.8% | -2.2% | 7.7% | -17.1% | 0.5% | -2.7% | -12.9% | -10.2% | -6.1% |
| — | -80.4% | -53.6% | +95.1% | +873.8% | +18.0% | +159.3% | -67.4% | +108.1% | -20.4% | -319.2% | -422.5% | -4620.0% | |
| ROIC | 8.5% | -1.3% | 5.9% | 0.0% | 3.4% | -0.7% | 4.3% | -11.3% | 2.0% | -2.3% | -11.1% | -11.1% | -5.1% |
| — | -93.1% | +36.6% | +100.3% | +68.1% | +69.8% | +139.2% | -2.3% | +140.2% | -21.5% | -595.3% | -287.0% | -2167.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Emergent BioSolutions Inc.'s Debt/EBITDA ratio is 82.9x, up from 6.6x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 35.9% YoY to 5.01x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.09 | 1.09 | 1.14 | 1.26 | 1.20 | 1.40 | 1.33 | 2.27 | 1.39 | 1.35 | 1.26 | 0.96 | 1.18 |
| — | -21.8% | -14.4% | -44.4% | -13.3% | +3.6% | +5.4% | +136.0% | +18.1% | +31.5% | +70.2% | +76.4% | +115.1% | |
| Debt / EBITDA | 2.74 | 82.91 | 6.59 | 27.60 | 8.92 | 42.79 | 7.49 | — | 13.81 | — | — | — | — |
| — | +93.8% | -12.0% | — | -35.4% | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.01 | 5.01 | 5.76 | 5.66 | 6.32 | 3.69 | 2.88 | 1.06 | 1.08 | 1.04 | 1.07 | 1.08 | 0.98 |
| — | +35.9% | +100.4% | +436.0% | +483.3% | +253.4% | +168.5% | -2.0% | +10.2% | +5.9% | -73.5% | -72.5% | -77.8% | |
| Quick Ratio | 2.41 | 2.41 | 3.15 | 3.00 | 3.51 | 1.77 | 1.47 | 0.54 | 0.55 | 0.54 | 0.54 | 0.57 | 0.68 |
| — | +36.6% | +114.1% | +451.1% | +533.9% | +228.3% | +173.8% | -4.1% | -18.5% | -23.1% | -73.2% | -76.2% | -75.8% | |
| Interest Coverage | 1.86 | -1.13 | 5.05 | 0.03 | 3.31 | -0.29 | 8.67 | -6.74 | 1.64 | -1.90 | -0.18 | 0.56 | -7.69 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EBS stock.
Emergent BioSolutions Inc.'s current P/E is 8.6x. The average P/E over the last 2 quarters is 1.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Emergent BioSolutions Inc.'s current operating margin is 14.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Emergent BioSolutions Inc.'s business trajectory between earnings reports.